Bloomage Biotechnology sees profit dip in first half 2025

Bloomage Biotechnology Corporation reported a 19.57% decrease in operating revenue to CNY 2,260,691,517.33 and a 35.38% decrease in net profit attributable to shareholders to CNY 220,851,905.02 for the first half of 2025. This decline is primarily attributed to a reduction in income from innovative skin science transformation businesses. The company's overall gross profit margin remained high at 70.99%.

In the second quarter of 2025, the company incurred CNY 48,372,700.00 in asset impairment losses, including CNY 5,998,600.00 in credit impairment losses for accounts receivable and other receivables, and CNY 42,374,100.00 in asset impairment losses for inventory. These impairment provisions affected the profit for the second quarter.

The company continued its focus on strategic initiatives, including advancing biomanufacturing, medical aesthetics, and nutritional science. Raw material sales remained stable, while medical aesthetic terminal product sales decreased slightly, and innovative skin science transformation sales experienced a significant decline.